Stelara denied by insurance? Appeal and win.
A Stelara denial is not a verdict, it is the opening move in a review your plan fully expects you to challenge. Because ustekinumab now competes with a wave of interchangeable biosimilars, most denials hinge on a biosimilar-first or non-medical-switch rule, or on a step-therapy block demanding documented failure of a TNF inhibitor or conventional therapy before this IL-12/23 agent is approved for your moderate-to-severe Crohn's disease, ulcerative colitis, plaque psoriasis, or psoriatic arthritis. The appeals that succeed pin the exact ICD-10 anchor to the labeled indication, attach the objective severity record (a documented Mayo or CDAI score for IBD, BSA or PASI involvement for psoriasis), and supply the dated prior-therapy trail showing intolerance or inadequate response to the comparator the plan named. When a continuation request is at stake, we also show that an established response makes a forced switch a clinical risk, not a cost-neutral substitution. Build the record around those specifics and a reviewer has no clean ground left to stand on.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Why Stelara gets denied
- Step therapy or biosimilar-first requirement
- Prior-authorization criteria not documented
- Diagnosis or severity not evidenced
- Non-preferred formulary placement
What a winning appeal includes
- Confirmed diagnosis with severity measures
- Prior therapies tried, including any biosimilar trials, and outcomes
- Specialist (GI, derm, or rheum) support
- A letter of medical necessity mapped to criteria
How we approach the appeal
Document the diagnosis, severity, and prior-therapy failures, and request a step-therapy or biosimilar override where that is the basis.
Stelara appeal letter template
Copy this Stelara appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns IL-12/23 biologic denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Stelara denial I am appealing the denial of Stelara (ustekinumab). I request that the denial be overturned and Stelara approved. 1. The denial. [Insurer] denied Stelara stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Stelara is medically necessary for my condition. Document the diagnosis, severity, and prior-therapy failures, and request a step-therapy or biosimilar override where that is the basis. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Stelara within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Stelara denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
Why was Stelara denied?
Commonly a biosimilar-first or step-therapy requirement, or undocumented severity. Specialist documentation of prior failures is key.
Stelara denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.